Click here to get full coverage on When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - simplywall.st

When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit?  simplywall.st

When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - simplywall.st

Click here to get full coverage on AYTU | AYTU BioPharma, Inc. Common Financials - Revenue Breakdown - Quiver Quantitative

AYTU | AYTU BioPharma, Inc. Common Financials - Revenue Breakdown  Quiver Quantitative

AYTU | AYTU BioPharma, Inc. Common Financials - Revenue Breakdown - Quiver Quantitative

Click here to get full coverage on AYTU - Finviz

AYTU - Finviz

Click here to get full coverage on AYTU Forecast — Price Target — Prediction for 2027 - TradingView

AYTU Forecast — Price Target — Prediction for 2027  TradingView

AYTU Forecast — Price Target — Prediction for 2027 - TradingView

Click here to get full coverage on Earnings call transcript: Aytu BioPharma Q3 2026 reveals earnings miss - Investing.com

Earnings call transcript: Aytu BioPharma Q3 2026 reveals earnings miss  Investing.com

Earnings call transcript: Aytu BioPharma Q3 2026 reveals earnings miss - Investing.com

Click here to get full coverage on Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results - ACCESS Newswire

Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results  ACCESS Newswire

Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results - ACCESS Newswire

Click here to get full coverage on New Strong Sell Stocks for July 16th - Yahoo Finance

New Strong Sell Stocks for July 16th  Yahoo Finance

New Strong Sell Stocks for July 16th - Yahoo Finance

Click here to get full coverage on Aytu BioScience Inc (AYTU) Key Financial Ratios – Valuation, Profitability & More - Value Research

Aytu BioScience Inc (AYTU) Key Financial Ratios – Valuation, Profitability & More  Value Research

Aytu BioScience Inc (AYTU) Key Financial Ratios – Valuation, Profitability & More - Value Research

Click here to get full coverage on AYTU BIOSCIENCE ($AYTU) Releases Q3 2026 Earnings - Quiver Quantitative

AYTU BIOSCIENCE ($AYTU) Releases Q3 2026 Earnings  Quiver Quantitative

AYTU BIOSCIENCE ($AYTU) Releases Q3 2026 Earnings - Quiver Quantitative

Click here to get full coverage on Latest AYTU ETF News Today | Earnings, Events & Price Alerts - Intellectia AI

Latest AYTU ETF News Today | Earnings, Events & Price Alerts  Intellectia AI

Latest AYTU ETF News Today | Earnings, Events & Price Alerts - Intellectia AI

Click here to get full coverage on Aytu Biopharma Inc (AYTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Aytu Biopharma Inc (AYTU) Dividends & Stock Splits: Historical Payouts and Event Timeline  TradingKey

Aytu Biopharma Inc (AYTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Click here to get full coverage on AYTU Q2 2026 Earnings: Loss Per Share Misses by 1.88% as Stock Holds Up - Estimate Uncertainty - siam.in

AYTU Q2 2026 Earnings: Loss Per Share Misses by 1.88% as Stock Holds Up - Estimate Uncertainty  siam.in

AYTU Q2 2026 Earnings: Loss Per Share Misses by 1.88% as Stock Holds Up - Estimate Uncertainty - siam.in

Click here to get full coverage on Aytu BioPharma to commercialise Exxua for MDD in the US - Pharmaceutical Technology

Aytu BioPharma to commercialise Exxua for MDD in the US  Pharmaceutical Technology

Aytu BioPharma to commercialise Exxua for MDD in the US - Pharmaceutical Technology

Click here to get full coverage on Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long - simplywall.st

Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long  simplywall.st

Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long - simplywall.st

Click here to get full coverage on New Strong Sell Stocks for July 20th - Yahoo Finance

New Strong Sell Stocks for July 20th  Yahoo Finance

New Strong Sell Stocks for July 20th - Yahoo Finance

Click here to get full coverage on Aytu launches EXXUA, first selective 5-HT1A agonist for depression - Investing.com

Aytu launches EXXUA, first selective 5-HT1A agonist for depression  Investing.com

Aytu launches EXXUA, first selective 5-HT1A agonist for depression - Investing.com

Click here to get full coverage on Track Historical Revenue - Quiver Quantitative

Track Historical Revenue  Quiver Quantitative

Track Historical Revenue - Quiver Quantitative

Click here to get full coverage on Aytu BioPharma at Planet MicroCap: Strategic Shift to CNS Focus - Investing.com

Aytu BioPharma at Planet MicroCap: Strategic Shift to CNS Focus  Investing.com

Aytu BioPharma at Planet MicroCap: Strategic Shift to CNS Focus - Investing.com

Click here to get full coverage on Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st

Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry  simplywall.st

Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Aytu (AYTU) Q2 2026 Earnings: EPS Misses Its Estimate; Closing Move: The Market Reaction Is Muted in the Current Update - Performance Review - vinanet.vn

Aytu (AYTU) Q2 2026 Earnings: EPS Misses Its Estimate; Closing Move: The Market Reaction Is Muted in the Current Update - Performance Review  vinanet.vn

Aytu (AYTU) Q2 2026 Earnings: EPS Misses Its Estimate; Closing Move: The Market Reaction Is Muted in the Current Update - Performance Review - vinanet.vn

Click here to get full coverage on AYTU Q2 2026 Earnings: EPS Misses Estimates, Shares Edge Higher - Post-Earnings Drift - vinanet.vn

AYTU Q2 2026 Earnings: EPS Misses Estimates, Shares Edge Higher - Post-Earnings Drift  vinanet.vn

AYTU Q2 2026 Earnings: EPS Misses Estimates, Shares Edge Higher - Post-Earnings Drift - vinanet.vn

Click here to get full coverage on Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini

Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd  Wilson Sonsini

Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini

Click here to get full coverage on Aytu BioPharma (AYTU) Edges Higher as Stock Tests Key Resistance - Overnight Profile - vinanet.vn

Aytu BioPharma (AYTU) Edges Higher as Stock Tests Key Resistance - Overnight Profile  vinanet.vn

Aytu BioPharma (AYTU) Edges Higher as Stock Tests Key Resistance - Overnight Profile - vinanet.vn

Click here to get full coverage on Aytu BioPharma Announces Indefinite Suspension of AR101 Clinical Development Program for vEDS - The Ehlers Danlos Society

Aytu BioPharma Announces Indefinite Suspension of AR101 Clinical Development Program for vEDS  The Ehlers Danlos Society

Aytu BioPharma Announces Indefinite Suspension of AR101 Clinical Development Program for vEDS - The Ehlers Danlos Society

Click here to get full coverage on CEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More Shares - Yahoo Finance

CEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More Shares  Yahoo Finance

CEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More Shares - Yahoo Finance

Click here to get full coverage on AYTU Q2 2026 Earnings: EPS Misses Estimates by Nearly 2%, Stock Holds Steady - Profit Announcement - vinanet.vn

AYTU Q2 2026 Earnings: EPS Misses Estimates by Nearly 2%, Stock Holds Steady - Profit Announcement  vinanet.vn

AYTU Q2 2026 Earnings: EPS Misses Estimates by Nearly 2%, Stock Holds Steady - Profit Announcement - vinanet.vn

Click here to get full coverage on Aytu (AYTU) Q2 2026 Earnings: EPS Misses Its Estimate; Closing Move: The Market Reaction Is Muted in the Current Update - Cash Flow Report - dars.gov.et

Aytu (AYTU) Q2 2026 Earnings: EPS Misses Its Estimate; Closing Move: The Market Reaction Is Muted in the Current Update - Cash Flow Report  dars.gov.et

Aytu (AYTU) Q2 2026 Earnings: EPS Misses Its Estimate; Closing Move: The Market Reaction Is Muted in the Current Update - Cash Flow Report - dars.gov.et

Click here to get full coverage on Aytu BioPharma (AYTU) Climbs 3.72% to $2.23 — Approaching Key Resistance - Breadth Thrust - vinanet.vn

Aytu BioPharma (AYTU) Climbs 3.72% to $2.23 — Approaching Key Resistance - Breadth Thrust  vinanet.vn

Aytu BioPharma (AYTU) Climbs 3.72% to $2.23 — Approaching Key Resistance - Breadth Thrust - vinanet.vn

Click here to get full coverage on Aytu BioPharma Shares Drop 5.45% — Support Level in Focus (AYTU) - Regression Channel - dars.gov.et

Aytu BioPharma Shares Drop 5.45% — Support Level in Focus (AYTU) - Regression Channel  dars.gov.et

Aytu BioPharma Shares Drop 5.45% — Support Level in Focus (AYTU) - Regression Channel - dars.gov.et

Click here to get full coverage on AYTU Q2 2026 Earnings: EPS Slightly Misses Estimates with Minimal Surprise - Performance Review - vinanet.vn

AYTU Q2 2026 Earnings: EPS Slightly Misses Estimates with Minimal Surprise - Performance Review  vinanet.vn

AYTU Q2 2026 Earnings: EPS Slightly Misses Estimates with Minimal Surprise - Performance Review - vinanet.vn

Click here to get full coverage on AYTU Q2 2026 Earnings: Narrow EPS Miss Slightly Wider Than Expected, Shares Rise 1.69% - Post-Earnings Reaction - dars.gov.et

AYTU Q2 2026 Earnings: Narrow EPS Miss Slightly Wider Than Expected, Shares Rise 1.69% - Post-Earnings Reaction  dars.gov.et

AYTU Q2 2026 Earnings: Narrow EPS Miss Slightly Wider Than Expected, Shares Rise 1.69% - Post-Earnings Reaction - dars.gov.et

Click here to get full coverage on AYTU Q2 2026 Earnings: EPS Misses Consensus, Stock Falls Slightly - Revenue Guidance Update - vinanet.vn

AYTU Q2 2026 Earnings: EPS Misses Consensus, Stock Falls Slightly - Revenue Guidance Update  vinanet.vn

AYTU Q2 2026 Earnings: EPS Misses Consensus, Stock Falls Slightly - Revenue Guidance Update - vinanet.vn

Click here to get full coverage on AYTU Q2 2026 Earnings: EPS Misses Estimates Amid Narrow Loss; Stock Edges Higher - Post-Earnings Drift - vinanet.vn

AYTU Q2 2026 Earnings: EPS Misses Estimates Amid Narrow Loss; Stock Edges Higher - Post-Earnings Drift  vinanet.vn

AYTU Q2 2026 Earnings: EPS Misses Estimates Amid Narrow Loss; Stock Edges Higher - Post-Earnings Drift - vinanet.vn

Click here to get full coverage on What is the current Price Target and Forecast for Aytu BioPharma, Inc. (AYTU) - Zacks Investment Research

What is the current Price Target and Forecast for Aytu BioPharma, Inc. (AYTU)  Zacks Investment Research

What is the current Price Target and Forecast for Aytu BioPharma, Inc. (AYTU) - Zacks Investment Research

Click here to get full coverage on AYTU Q2 2026 Earnings: EPS Misses Estimates, Shares Edge Higher - Segment Revenue Breakdown - dars.gov.et

AYTU Q2 2026 Earnings: EPS Misses Estimates, Shares Edge Higher - Segment Revenue Breakdown  dars.gov.et

AYTU Q2 2026 Earnings: EPS Misses Estimates, Shares Edge Higher - Segment Revenue Breakdown - dars.gov.et

Click here to get full coverage on Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals - ACCESS Newswire

Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals  ACCESS Newswire

Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals - ACCESS Newswire

Click here to get full coverage on Aytu Biopharma (AYTU) Stock Price, News & Analysis - Stock Titan

Aytu Biopharma (AYTU) Stock Price, News & Analysis  Stock Titan

Aytu Biopharma (AYTU) Stock Price, News & Analysis - Stock Titan

Click here to get full coverage on Armistice Capital Overcomes Novel Ruling in Aytu Stock Case (1) - news.bloomberglaw.com

Armistice Capital Overcomes Novel Ruling in Aytu Stock Case (1)  news.bloomberglaw.com

Armistice Capital Overcomes Novel Ruling in Aytu Stock Case (1) - news.bloomberglaw.com

Click here to get full coverage on Opinion | An Experimental Ultraviolet Light Treatment for Covid-19 Takes Political Heat - WSJ

Opinion | An Experimental Ultraviolet Light Treatment for Covid-19 Takes Political Heat  WSJ

Opinion | An Experimental Ultraviolet Light Treatment for Covid-19 Takes Political Heat - WSJ

Click here to get full coverage on Aytu BioPharma Completes $15 Million Debt Refinancing - ACCESS Newswire

Aytu BioPharma Completes $15 Million Debt Refinancing  ACCESS Newswire

Aytu BioPharma Completes $15 Million Debt Refinancing - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma Rallies as Shares Test Key Resistance Levels - Triple Bottom - dars.gov.et

Aytu BioPharma Rallies as Shares Test Key Resistance Levels - Triple Bottom  dars.gov.et

Aytu BioPharma Rallies as Shares Test Key Resistance Levels - Triple Bottom - dars.gov.et

Click here to get full coverage on Aytu BioPharma (AYTU) Slips 1.7% to $2.36 as Biotech Volatility Persists - Zigzag Correction - dars.gov.et

Aytu BioPharma (AYTU) Slips 1.7% to $2.36 as Biotech Volatility Persists - Zigzag Correction  dars.gov.et

Aytu BioPharma (AYTU) Slips 1.7% to $2.36 as Biotech Volatility Persists - Zigzag Correction - dars.gov.et

Click here to get full coverage on Aytu Begins Phase 3 Trial of AR101, Possible Vascular EDS Treatment - Ehlers-Danlos News

Aytu Begins Phase 3 Trial of AR101, Possible Vascular EDS Treatment  Ehlers-Danlos News

Aytu Begins Phase 3 Trial of AR101, Possible Vascular EDS Treatment - Ehlers-Danlos News

Click here to get full coverage on Aytu BioPharma (AYTU) Edges Higher as Stock Tests Key Resistance - Cash Flow Strong Stocks - dars.gov.et

Aytu BioPharma (AYTU) Edges Higher as Stock Tests Key Resistance - Cash Flow Strong Stocks  dars.gov.et

Aytu BioPharma (AYTU) Edges Higher as Stock Tests Key Resistance - Cash Flow Strong Stocks - dars.gov.et

Click here to get full coverage on AYTU Q1 2026 Earnings: EPS Misses Estimates, Revenue Context Limited - Annual Report - dars.gov.et

AYTU Q1 2026 Earnings: EPS Misses Estimates, Revenue Context Limited - Annual Report  dars.gov.et

AYTU Q1 2026 Earnings: EPS Misses Estimates, Revenue Context Limited - Annual Report - dars.gov.et

Click here to get full coverage on Aytu BioPharma to commercialise Exxua antidepressant in US - World Pharmaceutical Frontiers

Aytu BioPharma to commercialise Exxua antidepressant in US  World Pharmaceutical Frontiers

Aytu BioPharma to commercialise Exxua antidepressant in US - World Pharmaceutical Frontiers

Click here to get full coverage on Aytu BioPharma Acquires License to Develop DB102 for vEDS - Ehlers-Danlos News

Aytu BioPharma Acquires License to Develop DB102 for vEDS  Ehlers-Danlos News

Aytu BioPharma Acquires License to Develop DB102 for vEDS - Ehlers-Danlos News

Click here to get full coverage on AYTU Stock Price and Chart — NASDAQ:AYTU - TradingView

AYTU Stock Price and Chart — NASDAQ:AYTU  TradingView

AYTU Stock Price and Chart — NASDAQ:AYTU - TradingView

Click here to get full coverage on Aytu Bioscience Stock Price Forecast. Should You Buy AYTU? - StockInvest.us

Aytu Bioscience Stock Price Forecast. Should You Buy AYTU?  StockInvest.us

Aytu Bioscience Stock Price Forecast. Should You Buy AYTU? - StockInvest.us

Click here to get full coverage on AYTU BIOPHARMA Executives Increase Stake in Company - TradingView

AYTU BIOPHARMA Executives Increase Stake in Company  TradingView

AYTU BIOPHARMA Executives Increase Stake in Company - TradingView

Click here to get full coverage on AYTU Forecast — Price Prediction for 2026. Should I Buy AYTU? - Intellectia AI

AYTU Forecast — Price Prediction for 2026. Should I Buy AYTU?  Intellectia AI

AYTU Forecast — Price Prediction for 2026. Should I Buy AYTU? - Intellectia AI

Click here to get full coverage on Aytu BioPharma Inc (AYTU) sentiment score, message volume, participation score and buzz level - Stocktwits

Aytu BioPharma Inc (AYTU) sentiment score, message volume, participation score and buzz level  Stocktwits

Aytu BioPharma Inc (AYTU) sentiment score, message volume, participation score and buzz level - Stocktwits

Click here to get full coverage on Armistice Capital Sued for ‘Looting,’ Insider Trades at Aytu Bio - news.bloomberglaw.com

Armistice Capital Sued for ‘Looting,’ Insider Trades at Aytu Bio  news.bloomberglaw.com

Armistice Capital Sued for ‘Looting,’ Insider Trades at Aytu Bio - news.bloomberglaw.com

Click here to get full coverage on Use of antibody tests Pitkin County purchased still are not FDA approved - AspenTimes.com

Use of antibody tests Pitkin County purchased still are not FDA approved  AspenTimes.com

Use of antibody tests Pitkin County purchased still are not FDA approved - AspenTimes.com

Click here to get full coverage on EDGAR Filing Documents for 0001654954-19-011709 - sec.gov

EDGAR Filing Documents for 0001654954-19-011709  sec.gov

EDGAR Filing Documents for 0001654954-19-011709 - sec.gov

Click here to get full coverage on Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results - ACCESS Newswire

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results  ACCESS Newswire

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results - ACCESS Newswire

Click here to get full coverage on Adzenys XR-ODT is FDA-Approved as Bioequivalent to Adderall XR - sec.gov

Adzenys XR-ODT is FDA-Approved as Bioequivalent to Adderall XR  sec.gov

Adzenys XR-ODT is FDA-Approved as Bioequivalent to Adderall XR - sec.gov

Click here to get full coverage on Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire

Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome  ACCESS Newswire

Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma, Inc. (AYTU) Latest Stock News & Headlines - Yahoo Finance

Aytu BioPharma, Inc. (AYTU) Latest Stock News & Headlines  Yahoo Finance

Aytu BioPharma, Inc. (AYTU) Latest Stock News & Headlines - Yahoo Finance

Click here to get full coverage on Aytu BioScience Announces the Acquisition of Nuelle, Inc., Developer and Marketer of Fiera® Female Personal Care Device - PR Newswire

Aytu BioScience Announces the Acquisition of Nuelle, Inc., Developer and Marketer of Fiera® Female Personal Care Device  PR Newswire

Aytu BioScience Announces the Acquisition of Nuelle, Inc., Developer and Marketer of Fiera® Female Personal Care Device - PR Newswire

Click here to get full coverage on Aytu BioPharma, Inc. (AYTU) Company Profile & Facts - Yahoo Finance

Aytu BioPharma, Inc. (AYTU) Company Profile & Facts  Yahoo Finance

Aytu BioPharma, Inc. (AYTU) Company Profile & Facts - Yahoo Finance

Click here to get full coverage on Should I buy Aytu BioPharma, Inc. (AYTU) - Zacks Investment Research

Should I buy Aytu BioPharma, Inc. (AYTU)  Zacks Investment Research

Should I buy Aytu BioPharma, Inc. (AYTU) - Zacks Investment Research

Click here to get full coverage on YouTube Removes Video On Possible Coronavirus Treatment Based On UV Rays - i24NEWS

YouTube Removes Video On Possible Coronavirus Treatment Based On UV Rays  i24NEWS

YouTube Removes Video On Possible Coronavirus Treatment Based On UV Rays - i24NEWS

Click here to get full coverage on AYTU BioPharma’s Market Rally: A New Dawn? - timothysykes.com

AYTU BioPharma’s Market Rally: A New Dawn?  timothysykes.com

AYTU BioPharma’s Market Rally: A New Dawn? - timothysykes.com

Click here to get full coverage on Aytu BioScience Announces Split-Adjusted Trading of its Common Stock - PR Newswire

Aytu BioScience Announces Split-Adjusted Trading of its Common Stock  PR Newswire

Aytu BioScience Announces Split-Adjusted Trading of its Common Stock - PR Newswire

Click here to get full coverage on Aytu BioScience Expands MiOXSYS Distribution Network With A Fertility-Focused Company In Over 20 Countries In Europe - BioSpace

Aytu BioScience Expands MiOXSYS Distribution Network With A Fertility-Focused Company In Over 20 Countries In Europe  BioSpace

Aytu BioScience Expands MiOXSYS Distribution Network With A Fertility-Focused Company In Over 20 Countries In Europe - BioSpace

Click here to get full coverage on Aytu BioSciences' (NASDAQ: AYTU), MiOXSYS® Male Infertility Diagnostic Device Gains Global Interest - Issuewire.com

Aytu BioSciences' (NASDAQ: AYTU), MiOXSYS® Male Infertility Diagnostic Device Gains Global Interest  Issuewire.com

AYTU

Price Chart

Key Statistics

Technicals

About AYTU

Latest News

When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - simplywall.st

AYTU | AYTU BioPharma, Inc. Common Financials - Revenue Breakdown - Quiver Quantitative

AYTU - Finviz

Advanced Charts

Top Gainers

Top Losers